Biopolymers modified with superoxide dismutase mimics

a technology of superoxide dismutase and biopolymer, which is applied in the direction of prosthesis, iron organic compounds, blood vessels, etc., can solve the problems of inability to work, inability to adapt to the environment, so as to improve the resistance of biomaterials to degradation and reduce the inflammatory response

Inactive Publication Date: 2006-04-27
PHARMACIA CORP
View PDF48 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013] Applicants have discovered that the modification of biomaterials with non-proteinaceous catalysts for the dismutation of superoxide greatly improves the biomaterial's resistance to degradation and reduces the inflammatory response. Thus, the present invention is directed to biomaterials which have been modified with non-proteinaceous catalysts for the dismutation of superoxide, or precursor ligands of non-proteinaceous catalysts for the dismutation of superoxide.

Problems solved by technology

However, they have inferior wear characteristics when compared with either cobalt-chromium-molybdenum alloys or 300 series stainless steel.
They also have the further disadvantage of being difficult to work.
These steels are, however, even less resistant to corrosion and hence more susceptible to corrosion fatigue.
However, as mentioned above, certain alloys corrode within the body and, as a result, dissolved metallic ions can produce adverse effects on the surrounding cells and can result in implant breakage.
But when used under the load of walking or the like, they may not remain fixed to the bone.
However, bioactive ceramics such as hydroxyapatite and tricalcium phosphate are relatively brittle and can fail under the loads in the human body.
However, polymers used in orthopedic devices such as hip and knee joints have a tendency for wear and build-up of fine debris, resulting in a painful inflammatory response.
For instance, thrombogenesis has posed a perennial problem for the use of biomaterials in hemodialysis membranes.
Although most biomaterials in current use are considered non-toxic, implanted biomaterial devices are seen as foreign bodies by the immune system, and so elicit a well characterized inflammatory response.
In addition, chemical modification has posed several difficulties.
Because of the unique chemical characteristics of each biomaterial and bioactive molecule, covalent linkage of the desired bioactive molecule to the biomaterial is not always possible.
Finally, the fact that many biologically active substances are heat liable has prevented their use with biomaterials that are molded or worked at high temperatures.
The impact of continual attempts by the organism to degrade biomaterial implants can lead to increased morbidity and device failure.
In the case of polyurethane pacemaker lead wire coatings, this results in polymer degradation and steady loss of function.
In the use of synthetic vascular grafts, this results in persistent thrombosis, improper healing, and restenosis.
As mentioned above, orthopedic devices such as hip and knee joints have a tendency for wear and build-up of fine debris resulting in a painful inflammatory response.
In addition, the surrounding tissue does not properly heal and integrate into the prosthetic device, leading to device loosening and opportunistic bacterial infections.
It has been proposed by many researchers that chronic inflammation at the site of implantation leads to the exhaustion of the macrophages and neutrophils, and an inability to fight off infection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biopolymers modified with superoxide dismutase mimics
  • Biopolymers modified with superoxide dismutase mimics
  • Biopolymers modified with superoxide dismutase mimics

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Compounds Used in Template Synthesis

[0130] Chemicals, Solvents, and Materials. UV Grade Acetonitrile (015-4) and Water (AH365-4) were obtained from Burdick & Jackson (Muskegon, Mich.). Isopropanol (27,049-0), R,R-1,2-diaminocyclohexane (34,672-1), 2,6-diacetylpyridine (D880-1), 2,6-pyridinedicarboxaldehyde (25,600-5), and trifluoroacetic acid (T6508) were purchased from Aldrich (Milwaukee, Wis.). 2-(N-morpholino)-ethanesulfonic acid (475893) and its sodium salt (475894) were purchased from Calbiochem (La Jolla, Calif.).

[0131] N-(triphenylmethyl)-(1R, 2R)-diaminocyclohexane: To a solution of (1R,2R)-diaminocyclohexane (250 g, 2.19 mol) in anhydrous CH2Cl2 (3.5 L) at 0° C. was added, dropwise, a solution of trityl chloride (254 g, 912 mol) in anhydrous CH2Cl2 (2 L) over 4 h. The resulting mixture was allowed to warm to RT and stirred overnight. The reaction mixture was washed with water until the pH of the aqueous washes was below 8 (4×2 L) and dried over Na2SO4. Filt...

example 2

Template Synthesis of Compound 38

[0135] (Manganese (II) dichloro{(4R,9R,14R,19R)-3,10,13,20,26-pentaazatetracyclo [20.3.1.04,9.014,19]hexacosa-[(26),22(23),24-triene}]. In a 5-L flask N,N′-Bis {(1R,2R)-[2-(amino)]cyclohexyl}-1,2-diaminoethane tetrahydrochloride, (93.5 g, 234 mmol), was suspended in ethanol (3 L), treated with solid KOH (59.6 g of 88% material, 934 mmol), and the resultant mixture stirred at RT for 1 h. MnCl2 (anhydrous, 29.4 g, 233.5 mmol) was then added in one portion and the reaction was stirred at RT for 15 min. To this suspension was added 2,6-pyridinedicarboxaldehyde (31.6 g, 233.5 mmol) and the resulting mixture was refluxed overnight. After 16 h, the template reaction was complete: MS (LRFAB) m / z 443 [M−Cl]+. See accompanying HPLC analyses. This material was taken on to the next step “as is”. The reaction mixture containing the template product in ethanol was cooled to RT and treated (cautiously under Argon flow) with 10% Pd(C) (˜100 g in portions over the n...

example 3

Template Synthesis of Compound 40

[0136] [Manganese(II)dichloro(4R,9R,11R,14R,19R)-3,10,13,20,26-pentaaza-(2R,21R)-dimethyltetracyclo[20.3.1.04.9.014,19] hexacose-1(25),22(26),23-triene, To a stirred solution of N,N′-Bis{(1R,2R)-[2-(amino)]cyclohexyl}-1,2-diaminoethane tetrahydrochloride (4.00 g, 10.0 mmol) in absolute ethanol (100 mL) was added KOH (2.55 g of ˜88% material, 40.0 mmol) and the mixture was stirred at RT for 30 min. under an Ar atmosphere. MnCl2 (anhydrous, 1.26 g, 10.0 mmol) was then added and the suspension stirred for an additional 30 min. or until MnCl2 dissolved. At this point, 2,6-diacetylpyridine (1.63 g, 10.0 mmol) was added to the green mixture and after 30 minutes heating commenced. After refluxing for 5 d, the mixture was dark red-brown. Mass spectrometry and HPLC analyses showed that the reaction had gone to 395% completion to give the bisimine Mn(II) complex (−94% purity by HPLC): ESI-MS: m / z (relative intensity) 471 / 473 (100 / 32) [M−Cl]+; only traces of d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weight percentaaaaaaaaaa
weight percentaaaaaaaaaa
weight percentaaaaaaaaaa
Login to view more

Abstract

This invention provides modified biopolymers comprising biopolymers attached to at least one non-proteinaceous catalyst capable of dismutating superoxide in the biological system or precursor ligand thereof. The invention further provides pharmaceutical compositions comprising the modified biopolymer and therapeutic methods comprising administering the modified biopolymer to a subject in need thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. Ser. No. 10 / 702,407, filed Nov. 5, 2003, which is a continuation of U.S. Ser. No. 09 / 580,007, filed May 26, 2000, which claims priority from provisional application No. 60 / 136,298 filed May 27, 1999, which are hereby incorporated by reference in their entirety for all purposes.BACKGROUND OF THE INVENTION [0002] The present invention relates to biomaterials modified with non-proteinaceous catalysts for the dismutation of superoxide, and processes for making such materials. This modification may be by covalent conjugation, copolymerization, or admixture of the non-proteinaceous catalysts with the biomaterial. The resulting modified biomaterials exhibit a marked decrease in inflammatory response and subsequent degradation when placed in contact with vertebrate biological systems. [0003]“Biomaterial” is a term given to a wide variety of materials which are generally considered appropriate for use i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61F2/06C08B37/00A61F2/82A61L27/00C07F13/00C07F15/02
CPCA61L27/20A61L31/042C07F13/005C07F15/025C08B15/00C08B15/05C08B37/00C08B37/003C08B37/0072C08G18/10C08G18/4854C08G18/6685C08G18/718C08G18/73C08H1/06C08L5/08C08G18/3228
Inventor ORNBERG, RICHARD L.UDIPI, KISHOREFORSTER, DENISRILEY, DENNIS P.THURMOND, KENNETH B.HENKE, SUSANBRETHAUER, KERRYJOARDAR, SAIKAT
Owner PHARMACIA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products